“Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome” (2025) Journal of Carcinogenesis, 24(3s), pp. 441–448. doi:10.64149/J.Carcinog.24.3s.441-448.